ARIF SHOAIB: Open Payments
NPI 1407838394 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,207 in 71 payments from 17 companies in 2025. Trend: 2023 $1,793 · 2024 $2,081 · 2025 $2,207
Food & beverage: $2,207
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $461 |
| Otsuka America Pharmaceutical, Inc. | 13 | $410 |
| Axsome Therapeutics, Inc. | 10 | $387 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $284 |
| Teva Pharmaceuticals USA, Inc. | 1 | $123 |
| ABBVIE INC. | 5 | $112 |
| Noven Therapeutics, LLC | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| Lundbeck LLC | 2 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
Products named: COBENFY, Auvelity, CAPLYTA, ABILIFY MAINTENA, REXULTI, UZEDY, VRAYLAR, Xelstrym.
Industry payments across TX — which companies pay providers there.
